Baltimore Mayor Scott releases preliminary plan to curb city opioid overdoses
The plan is part of an executive order detailing how the city will spend $242.5 million in settlement funds won in a lawsuit against multiple pharmaceutical companies.
Data on opioid overdoses in Baltimore City
According to Baltimore City's Overdose Needs Assessment, overdose deaths are declining – but the city still leads metro areas nationally in overdose mortality.
Black male residents who are 60 and older are 4.6 times as likely to experience a fatal overdose compared to their white counterparts. The leading cause of maternal mortality in Maryland is overdose, the city's report cited.
What is the plan to reduce overdoses?
The overall goals of the city's preliminary plan include addressing inequities in the overdose crisis, dismantling silos and improving connections within care systems, reducing the stigma surrounding care, and improving the quality and accessibility of substance use services across the city.
The city said that when community members lack access to housing, food, employment, and transportation, their access to harm reduction, treatment, and recovery services can be impeded.
Housing is the most essential need to support those who use drugs, according to the assessment.
The report also highlights a need to increase youth engagement programming in the city. Other needs included in the assessment are public health education and awareness campaigns, expanded access to mental health services, and more harm reduction spaces. In a community input form, community members said pharmacy access was also an issue.
What are the next steps?
Mayor Scott says his goal is to reduce fatal overdoses by 40% by 2040.
"This is a major milestone in our work to end the overdose crisis in our city and address decades of harm done to our residents," Scott said. "We made the decision to directly take on Big Pharma for their role in this crisis, and we won millions in settlements and awards. This strategic plan lays out how we'll invest that money back into communities, with the goal of reducing fatal overdoses at least 40% by 2040."
The city will hold four listening sessions in July where residents can provide feedback on the plan:
Wednesday, July 9: 5:30–8:00 p.m. at Cherry Hill Elementary and Middle School, 801 Bridgeway Rd., Baltimore, MD 21225
Thursday, July 17: 5:30–8:00 p.m. at Gethsemane Baptist Church, 2520 Francis St., Baltimore, MD 21217
Wednesday, July 23: 5:30–8:00 p.m. at Pimlico Elementary School, 4849 Pimlico Rd., Baltimore, MD 21215
Thursday, July 31: 5:30–8:00 p.m. at Henderson Hopkins Elementary and Middle School, 2100 Ashland Ave., Baltimore, MD 21205
The full Overdose Response Strategic Plan is available here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Ousted vaccine panel members say rigorous science is being abandoned
NEW YORK (AP) — The 17 experts who were ousted from a government vaccine committee last month say they have little faith in what the panel has become, and have outlined possible alternative ways to make U.S. vaccine policy. U.S. Health Secretary Robert F. Kennedy Jr. abruptly fired the entire Advisory Committee on Immunization Practices, accusing them of being too closely aligned with manufacturers and of rubber-stamping vaccines. He handpicked replacements that include several vaccine skeptics. In a commentary published Wednesday in the New England Journal of Medicine, the former panel members wrote that Kennedy — a leading voice in the anti-vaccine movement before becoming the U.S. government's top health official — and his new panel are abandoning rigorous scientific review and open deliberation. That was clear, they said, during the new panel's first meeting, in June. It featured a presentation by an anti-vaccine advocate that warned of dangers about a preservative used in a few flu vaccines, but the committee members didn't hear from Centers for Disease Control and Prevention staffers about an analysis that concluded there was no link between the preservative and neurodevelopmental disorders. The new panel recommended that the preservative, thimerosal, be removed even as some members acknowledged there was no proof it was causing harm. 'That meeting was a travesty, honestly,' said former ACIP member Dr. Yvonne Maldonado, a pediatric infectious diseases expert at Stanford University. The 17 discharged experts last month published a shorter essay in the Journal of the American Medical Association that decried Kennedy's 'destabilizing decisions." The focus was largely on their termination and on Kennedy's decision in May to stop recommending COVID-19 vaccines for healthy children and pregnant women. In the new commentary, the ousted committee members took it one step further and prescribed some steps that could be taken to maintain scientifically sound vaccine recommendations. 'An alternative to the Committee should be established quickly and — if necessary — independently from the federal government," they wrote. 'No viable pathway exists to fully replace the prior trusted and unbiased ACIP structure and process. Instead, the alternatives must focus on limiting the damage to vaccination policy in the United States.' Options included having professional organizations working together to harmonize vaccine recommendations or establishing an external auditor of ACIP recommendations. There are huge challenges to the ideas, including having access to the best data, the authors acknowledged. There's also the question of whether health insurers would pay for vaccinations that are recommended by alternative groups but not ACIP. They might pick and choose which vaccines to cover, said the University of North Carolina's Noel Brewer, another former ACIP member. For example, they might pay for vaccines that offer more immediate cost savings for health care, like the flu vaccine. 'But maybe not ones that have a longer-term benefit like HPV vaccine,' which is designed to prevent futures cancers, Brewer said. Officials with the U.S. Department of Health and Human Services did not immediately respond to a request for comment. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Solve the daily Crossword
Yahoo
19 minutes ago
- Yahoo
Recall issued over energy drinks mistakenly containing vodka
MODESTO, Calif. (AP) — Energy drinks that mistakenly contain vodka are being recalled in half a dozen states. High Noon is recalling two production lots of High Noon Beach Variety packs because some packs include cans containing vodka that were mislabeled as Celsius Astro Vibe Energy Drink, according to a U.S. Food and Drug Administration recall notice Wednesday. The cans contain vodka seltzer and were mislabeled as 'sparkling blue razz'-flavored Celsius Astro Vibe energy drinks, the notice said. Consumption of the liquid in the cans will result in 'unintentional alcohol ingestion,' the company said. The packs were distributed to retailers in Florida, New York, Ohio, South Carolina, Virginia and Wisconsin. The recall was initiated after the company discovered that a shared packaging supplier mistakenly shipped empty Celsius energy drink cans to High Noon. No illnesses or adverse events have been reported related to the labeling error, according to the company. Consumers who purchased the beverages with the impacted codes found in the recall notice should dispose of it, the notice said. Consumers are also encouraged to make sure any Sparkling Blue Razz Celsius Astro Vibe energy drinks do not contain the specific lot codes in the notice before drinking them. The Associated Press Sign in to access your portfolio
Wall Street Journal
19 minutes ago
- Wall Street Journal
WSJ Opinion: The FDA's Gene-Therapy Reversal and the Exit of Vinay Prasad
A top official at the Food and Drug Administration steps down after the agency changes course on a treatment for Duchenne muscular dystrophy. What does this say about the Trump Administration's approach toward drug innovation?
